"A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The N-ABLE Study)"

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Bladder Cancer
Interventions
BIOLOGICAL

CDX-1307 Vaccine Regimen

CDX-1307 vaccine co-administered with immune adjuvants (GM-CSF, Poly-ICLC and Resiquimod)

DRUG

Chemotherapy

Trial Locations (17)

10021

Weill Cornell Medical College, New York

13210

SUNY Upstate Medical University, Syracuse

Syracuse VA Medical Center, Syracuse

14263

Roswell Park Cancer Center, Buffalo

14642

University of Rochester, Rochester

19107

Thomas Jefferson University, Philadelphia

21201

University of Maryland Greenebaum Cancer Center, Baltimore

32610

University of Florida, Gainesville

33612

Moffitt Cancer Center, Tampa

48202

Henry Ford Health System, Detroit

52242

University of Iowa Hospitals and Clinics, Iowa City

63110

Washington University School of Medicine, St Louis

80045

University of Colorado Cancer Center, Aurora

85032

BCG Oncology, PC, Phoenix

90033

University of Southern California Norris Comprehensive Cancer Center LA-USC Medical Center, Los Angeles

92093

University of California - San Diego, La Jolla

40536-0093

University of Kentucky Markey Cancer Center Clinical Research Organization, Lexington

Sponsors
All Listed Sponsors
lead

Celldex Therapeutics

INDUSTRY

NCT01094496 - "A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The N-ABLE Study)" | Biotech Hunter | Biotech Hunter